Prof. Markus J. Barten, Germany
MANDELA study results at 18 months after heart transplantation: Superior renal function with cni-free everolimus over standard CNI-based regimen: A randomized, multi-center trial in de novo heart transplant recipients. (Video Available)

Dr. Federico Oppenheimer, Spain
Renal function outcomes in de novo kidney transplant recipients receiving everolimus with reduced-exposure calcineurin inhibitor versus mycophenolate with standard-exposure calcineurin inhibitor: Results from the TRANSFORM study (Video Available)

Dr. Beatriz Suarez-Alvarez, Spain
Everolimus failure to counteract the cytotoxic response mediated by CD8+ T and NK cells in heart-transplant patients

Mr. Erlend J. Egeland, Norway
High tacrolimus clearance – a risk factor for development of interstitial fibrosis and tubular atrophy in the transplanted kidney (Video Available)

Dr. Lauren Brasile, United States
The feasibility of organ-specific immunosuppression (Video Available)

Prof. Bjoern Nashan, Germany
CD40 inhibition with CFZ533 - A new, fully human, non-depleting, Fc silent mAB - improves renal allograft function while demonstrating comparable efficacy vs. tacrolimus in de-novo CNI-Free kidney transplant recipients

Martijn W.F. van den Hoogen, Netherlands
Targeting the CD40-costimulation pathway by CFZ533 prevents the cross–talk between follicular T helper cells and B cells (Video Available)

Dr. Yeqi Nian, United States
Costimulatory blockade with CTLA4-Ig abrogates prolonged graft survival in old recipients

Julio Pascual, Spain
Efficacy and safety of everolimus with reduced-dose calcineurin inhibitor in de novo kidney transplant recipients: Results from the TRANSFORM study (Video Available)